Poly (amino acid) micelle nanocarriers in preclinical and clinical studies.
Polymeric micelles are expected to increase the accumulation of drugs in tumor tissues utilizing the EPR effect and to incorporate various kinds of drugs into the inner core by chemical conjugation or physical entrapment with relatively high stability. The size of the micelles can be controlled within the diameter range of 20 to 100 nm, to ensure that the micelles do not pass through normal vessel walls; therefore, a reduced incidence of the side effects of the drugs may be expected due to the decreased volume of distribution. These are several anticancer agent-incorporated micelle carrier systems under clinical evaluation. Phase 1 studies of a CDDP incorporated micelle, Nc-6004, and an sN-38 incorporated micelle, NK012, are now underway. A phase 2 study of a PTX incorporated micelle, NK105, against stomach cancer is also underway.
Matsumura
Yasuhiro
Y
Investigative Treatment Division, Research Center for Innovative Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa City, 277-8577 Japan.
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D002945:Cisplatin / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D004337:Drug Carriers / Q000737:chemistry; D004353:Drug Evaluation, Preclinical; D006801:Humans; D000077146:Irinotecan; D008823:Micelles; D053758:Nanoparticles / Q000737:chemistry*; D017239:Paclitaxel / Q000008:administration & dosage / Q000031:analogs & derivatives; D010316:Particle Size; D011108:Polymers / Q000737:chemistry
D000970:Antineoplastic Agents; D004337:Drug Carriers; D008823:Micelles; C500671:NK105; D011108:Polymers; D000077146:Irinotecan; D017239:Paclitaxel; D002945:Cisplatin; D002166:Camptothecin